ClinicalTrials.gg
CompletedNCT05997225Updated Nov 5, 2026Results posted

Tobacco Cessation at FDNY

A Phase 4 interventional study of opt out enrollment, tailored counseling, varenicline started prior to target quit date and opt in enrollment, non-tailored counseling, varenicline started prior to target quit date in Tobacco Use, Tobacco Smoking and Tobacco Use Cessation, sponsored by Albert Einstein College of Medicine. Completed at 1 site in United States. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Primary conditionTobacco SmokingRegistry: Tobacco UseReclassifiedWhy we changed it
Registry
Tobacco Use — the first condition term the registry derived for this study.
ClinicalTrials.gg
Tobacco Smoking
Why
  1. The study's listed conditions name Tobacco Smoking, a narrower term within Tobacco Use.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Albert Einstein College of Medicine · Phase 4, Interventional, and Treatment

How we know

Updated Nov 5, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 186 studies in Tobacco Smoking with a site in United States — 24 open to participants now, 30 under way, 2 of them phase 3. Tobacco Smoking · United States.

Enrollment
151st of 178
23 · median 111
Started
2024
with 11 others
Phase 4
10 of 186
1 open now
Registered
164th of 186
by date

Among the 186 studies in Tobacco Smoking with a site in United States, this one is the 151st largest by enrollment of the 178 interventional ones that give a count, is one of 12 that started in 2024, is one of 10 in phase 4, and was the 164th registered.

Tobacco Smoking

265 studies on the registry are indexed under Tobacco Smoking; 43 are open to participants now.

Browse Tobacco Smoking studies →

Open to participants now

24 of the 186 studies in Tobacco Smoking with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Tobacco Smoking studies recruiting now, 15 (44%) set no upper age limit and 17 (50%) stop at 75 or younger; 2 take children under 18; 17 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 186 studies in Tobacco Smoking with a site in United States, or all of them as a file.
02

Study summary

At the Fire Department of the City of New York (FDNY) World Trade Center Health Program, 36% of participants in the low dose computed tomography (LDCT) lung cancer screening program are current smokers, despite referral to the free FDNY Tobacco Cessation Program (Standard Care). Investigators propose testing an Enhanced Care program which includes opt-out enrollment; tobacco cessation counseling will be individually tailored to spirometry/LDCT results and treatment with varenicline starting 4 weeks prior to their target quit date. This randomized trial will compare enrollment and cessation outcomes in Standard Care vs. Enhanced Care groups of challenging-to-treat, high-risk smokers.

Read the detailed description

The overarching goal of this Randomized Controlled trial is to develop and test an effective, scalable intervention with potential to reach high-risk smokers undergoing CT lung cancer screening who have not engaged in or succeeded with traditional tobacco treatment approaches. The investigators will test an Enhanced Care intervention specifically designed to address multiple challenges to tobacco treatment engagement and success. First, the researchers will test opt-out enrollment in cessation treatment. The current tobacco treatment default, in which patients must opt-in to cessation treatment and are only offered counseling and pharmacotherapy when deemed ready to quit, results in missed opportunities to engage smokers into treatment. Previous studies of opt-out enrollment in cessation treatment suggest that an opt-out tobacco treatment strategy substantially increases engagement and cessation rates compared with traditional opt-in approaches. Second, proactive counseling will leverage the "reachable, teachable moment" of CT screening to motivate cessation through individually tailored messaging tied to CT results and lung function spirometry. Using CT results as a motivational tool has shown promise in pilot studies. The optimal approach and success of using CT coupled with spirometry results to motivate tobacco cessation remains unknown. Third, investigators will offer varenicline pre-loading to all enrollees, regardless of study arm, in which varenicline is initiated 4 weeks prior to target quit date. This approach is associated with decreased pre-quit tobacco-associated reward and double the rate of abstinence compared with standard varenicline treatment.

The investigators thus propose a randomized trial among retired FDNY World Trade Center Health Program responders eligible for the FDNY World Trade Center Health Program CT screening program to test the effects of Enhanced Care (opt-out enrollment, tailored counseling based on CT and spirometry results, and varenicline with preloading) against Standard Care (opt-in enrollment, standard cessation counseling without spirometry/CT tailoring, and varenicline with preloading) in the engagement of high-risk smokers in cessation treatment and the achievement of tobacco abstinence.

03

Conditions studied

  • Tobacco Use
  • Tobacco Smoking
  • Tobacco Use Cessation

Browse trials for

Keywords

  • World Trade Center Health Program
  • occupational medicine
  • tobacco cessation
  • lifestyle medicine
  • opt-out treatment
04

In context

Tobacco Smoking Reclassified

265 studies on the registry are indexed under Tobacco Smoking; 43 are open to participants now.

This study's enrollment of 23 is below the median of 120 across 230 interventional studies indexed under Tobacco Smoking.

Browse Tobacco Smoking studies →

Lead sponsor

Albert Einstein College of Medicine is the lead sponsor of 201 studies on the registry; 21 are open to participants now.

Of its 46 completed or terminated interventional studies of FDA-regulated products, 37 (80%) have results posted.

Compared within Tobacco Smoking, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Tobacco Use. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Enrolled in FDNY World Trade Center Health Program (WTCHP)
  • Retired
  • Age ≥ 50 years old
  • Self-reported current smoker on most recent questionnaire OR self-reported current smoker in the past 5 years
  • 20 pack-year smoker OR 20-year smoking duration

Exclusion criteria

Exclusion Criteria

  • Reduced renal function
  • estimated (eGFR) \<30 [CKD-EPI Creatinine Equation (2021)] at last World Trade Center (WTC) medical monitoring blood exam OR ICD10 codes for kidney disease: N04.9, N17.9, N18.9, Z94.0, E13.21, N18.9, I12.9, N00.9, N03.9
  • Undergoing active cancer treatment, defined as being diagnosed on 1/1/2022 or later
  • Clinical instability (e.g., hospitalization in last 3 months)
  • Using varenicline in last 30 days
  • Endorsing suicidal ideations: moderate or high risk on Columbia-Suicide Severity Rating Scale (C-SSRS)
  • Screened for alcohol use disorder AUDIT>15
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    Enhanced Care

    Opt-out counseling enrollment. individually-tailored biofeedback linked to Chest CT and spirometry results. Varenicline: Preloading regimen (prior to target quit date): 0.5 mg once a day for days 1-3, 0.5 mg twice a day for days 4-7, and 1 mg twice a day for days 8-28. 1 mg twice day for 12 weeks after target quit date.

    Other: opt out enrollment, tailored counseling, varenicline started prior to target quit date

  • Active comparator
    Standard Care

    Opt-in counseling enrollment. Standard tobacco cessation counseling. Varenicline: Preloading regimen (prior to target quit date): 0.5 mg once a day for days 1-3, 0.5 mg twice a day for days 4-7, and 1 mg twice a day for days 8-28. 1 mg twice day for 12 weeks after target quit date.

    Other: opt in enrollment, non-tailored counseling, varenicline started prior to target quit date

Interventions

  • Otheropt out enrollment, tailored counseling, varenicline started prior to target quit date

    Participants automatically enrolled in motivational counseling. Tailored counseling includes sharing results of Chest CT results and lung function spirometry tests with participants.

  • Otheropt in enrollment, non-tailored counseling, varenicline started prior to target quit date

    Participants must opt-in to receive counseling. Counseling does not include discussion of Chest CT or spirometry results.

07

What researchers measure

Primary outcomes

  1. Enrollment

    Enrollment is defined as all participants who completed at least one session with our tobacco treatment specialist in FDNY's Tobacco Cessation Program: Standard vs. Enhanced Care arms. The number of participants who attend at least one study visit with the tobacco treatment specialist from the eligible recruitment population will be tabulated and reported.

    Time frame: Baseline (Week 0)

  2. Number of Participants With (Biochemically Validated) Tobacco Abstinence

    7-day point prevalence abstinence will be biochemically verified by the analysis of urine samples collected at a laboratory nearest each participant's residence. Urine sample collection will occur at weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint at 28 weeks. Samples will be analyzed for urine cotinine which is the commonly measured biomarker of nicotine intake. Urine cotinine levels \< 20 ng/mL will be used to verify tobacco abstinence. Data will be summarized at each timepoint by study arm from weeks 2 - weeks 28 using basic descriptive statistics at each research assessment visit.

    Time frame: Weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint visit at 28 weeks

Secondary outcomes

  1. Retention to Study End-Date

    Retention will be assessed and reported as the number of participants retained in the study through the time of the 12-week post end of treatment (EOT) timepoint at 28 weeks.

    Time frame: Through the 12-week post EOT timepoint at 28 weeks

  2. Number of Participants Who Attended Counseling Visit at Each Timepoint - Counseling Adherence

    Counseling adherence will be determined by the number of counseling visits attended. Tobacco counseling sessions will occur at baseline, and at weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint at 28 weeks. Counseling adherence will be summarized by study arm based on attendance during each individual session (timepoint) and reported as a continuous variable for each timepoint (counseling visit).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, and the 12-week post EOT timepoint visit at 28 weeks

  3. Pill Count Percentage - Varenicline Adherence

    Varenicline adherence will be measured using pill count percentage, recorded as the number of pills taken divided by the number of pills prescribed, per participant, corresponding to the dosing regimen. Varenicline adherence data will be summarized by study arm using basic descriptive statistics for each week of treatment. Participants refusing medication will be counted as zero. Participants discontinuing medication due to reported side effects or adverse events will be excluded from calculation totals. Medication adherence rates in excess of 100% (e.g., subjects mistakenly took extra pills) will be reported as 100% adherence. Similarly, medication adherence rates below zero (e.g., subjects added pills to the bottle but did not remove any pills) will be reported as 0% adherence. Pill count adherence is an objective measure that has been shown to correlate with electronic monitors and varenicline plasma levels.

    Time frame: Baseline, Weeks 2, 4, 8, 12, and 16

08

Results

Posted Nov 5, 2026
Limitations and caveats
These results have limitations, including limited enrollment and retention. Since immediately after 9/11/2001, Fire Department of New York (FDNY) World Trade Center (WTC) responders have had access to tobacco cessation services, and many had already quit. This may have reduced enrollment in this study, as it is a well-studied cohort with prior exposure to cessation efforts. Given the low enrollment, the study was underpowered and unable to perform any inferential statistical analyses.

Participant flow

Randomization into Enhanced Care (EC) or Standard Care (SC) was completed prior to recruitment. Both treatment arms received a mailed recruitment letter. EC participants were instructed to contact the study coordinator if they wished to opt-out. SC participants received a mailed letter and were instructed to contact the coordinator if they wished to participate. The coordinator contacted EC participants to complete consent procedures and schedule visits. Recruitment procedures began in May 2024.

Participant flow — Overall Study
MilestoneEnhanced CareStandard Care
Started176
Completed42
Not completed134
Withdrew: Lost to follow-up114
Withdrew: Excluded20

Outcome measures

PrimaryEnrollment

Enrollment is defined as all participants who completed at least one session with our tobacco treatment specialist in FDNY's Tobacco Cessation Program: Standard vs. Enhanced Care arms. The number of participants who attend at least one study visit with the tobacco treatment specialist from the eligible recruitment population will be tabulated and reported.

Time frame:
Baseline (Week 0)
Reported as:
Count of participants · Participants
Enrollment
ParticipantsEnhanced CareStandard Care
Enrollment125
PrimaryNumber of Participants With (Biochemically Validated) Tobacco Abstinence

7-day point prevalence abstinence will be biochemically verified by the analysis of urine samples collected at a laboratory nearest each participant's residence. Urine sample collection will occur at weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint at 28 weeks. Samples will be analyzed for urine cotinine which is the commonly measured biomarker of nicotine intake. Urine cotinine levels \< 20 ng/mL will be used to verify tobacco abstinence. Data will be summarized at each timepoint by study arm from weeks 2 - weeks 28 using basic descriptive statistics at each research assessment visit.

Time frame:
Weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint visit at 28 weeks
Reported as:
Count of participants · Participants
Number of Participants With (Biochemically Validated) Tobacco Abstinence
ParticipantsEnhanced CareStandard Care
Week 200
Week 420
Week 823
Week 1223
Week 1622
Week 2812
SecondaryRetention to Study End-Date

Retention will be assessed and reported as the number of participants retained in the study through the time of the 12-week post end of treatment (EOT) timepoint at 28 weeks.

Time frame:
Through the 12-week post EOT timepoint at 28 weeks
Reported as:
Count of participants · Participants
Retention to Study End-Date
ParticipantsEnhanced CareStandard Care
Retention to Study End-Date42
SecondaryNumber of Participants Who Attended Counseling Visit at Each Timepoint - Counseling Adherence

Counseling adherence will be determined by the number of counseling visits attended. Tobacco counseling sessions will occur at baseline, and at weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint at 28 weeks. Counseling adherence will be summarized by study arm based on attendance during each individual session (timepoint) and reported as a continuous variable for each timepoint (counseling visit).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, and the 12-week post EOT timepoint visit at 28 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Attended Counseling Visit at Each Timepoint - Counseling Adherence
ParticipantsEnhanced CareStandard Care
Baseline125
Week 2103
Week 493
Week 873
Week 1273
Week 1663
Week 2842
SecondaryPill Count Percentage - Varenicline Adherence

Varenicline adherence will be measured using pill count percentage, recorded as the number of pills taken divided by the number of pills prescribed, per participant, corresponding to the dosing regimen. Varenicline adherence data will be summarized by study arm using basic descriptive statistics for each week of treatment. Participants refusing medication will be counted as zero. Participants discontinuing medication due to reported side effects or adverse events will be excluded from calculation totals. Medication adherence rates in excess of 100% (e.g., subjects mistakenly took extra pills) will be reported as 100% adherence. Similarly, medication adherence rates below zero (e.g., subjects added pills to the bottle but did not remove any pills) will be reported as 0% adherence. Pill count adherence is an objective measure that has been shown to correlate with electronic monitors and varenicline plasma levels.

Time frame:
Baseline, Weeks 2, 4, 8, 12, and 16
Reported as:
Mean · Pill Count Percentage
Pill Count Percentage - Varenicline Adherence
Pill Count PercentageEnhanced CareStandard Care
Week 279.23 (0 to 100)92.06 (76.19 to 100)
Week 465.63 (0 to 100)66.67 (0 to 100)
Week 850.00 (0 to 100)64.54 (0 to 100)
Week 1245.42 (0 to 100)59.89 (0 to 98.28)
Week 1625.00 (0 to 75)37.36 (0 to 100)
Post-hocEnrollment - Informed Consent

Enrollment - Informed Consent, defined as the number of participants who completed the study informed consent with the study coordinator indicating their intent to participate in the study, regardless of their attendance at the initial or subsequent study visitations. This quantity will be tabulated and reported as a percentage of the eligible recruitment populations by Standard vs. Enhanced Care arms. The time frame for this measure uses the completion date of the informed consent, prior to the Baseline (Week 0) study visit. Participants who completed informed consent but did not subsequently complete any study procedures were not followed or monitored and were recorded as lost to follow-up.

Time frame:
Prior to Baseline (Week 0)
Reported as:
Count of participants · Participants
Enrollment - Informed Consent
ParticipantsEnhanced CareStandard Care
Enrollment - Informed Consent176
Post-hocNumber of Participants With (Self-Report) Tobacco Abstinence

7-day self-reported tobacco abstinence will be assessed using self-report survey data collect at baseline and at weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint at 28 weeks, where participants were asked either "Do you now currently smoke cigarettes" at baseline, and "In the time since your last study visit, have you smoked any cigarettes (even a puff)". Data will be summarized at each timepoint by study arm using data from each research assessment with basic descriptive statistics. This measure was added as a supplemental outcome, to describe cessation results where collection of biomarker nicotine metabolites were not completed.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, and the 12-week post EOT timepoint visit at 28 weeks
Reported as:
Count of participants · Participants
Number of Participants With (Self-Report) Tobacco Abstinence
ParticipantsEnhanced CareStandard Care
Baseline00
Week 200
Week 420
Week 833
Week 1253
Week 1632
Week 2832
Post-hocNumber of Participants Who Demonstrate Cigarette Use Reduction

Number of participants who demonstrate a reduction in their average number of cigarettes smoked per day that is greater than or equal to at least 50% of the quantity of self-reported cigarettes smoked per day during their baseline survey. This single time point measure evaluates changes in smoking behavior. In the case of missing survey data, this measure was calculated using the most recent self-report survey data available, from weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint at 28 weeks. Counts are reported in units of number of participants, and are shown by study arm. During study analyses this outcome was added as a post-hoc outcome.

Time frame:
Latest data available, from self-report survey completed during weeks 2, 4, 8, 12, 16 and 12-week post end of treatment at 28 weeks.
Reported as:
Count of participants · Participants
Number of Participants Who Demonstrate Cigarette Use Reduction
ParticipantsEnhanced CareStandard Care
Number of Participants Who Demonstrate Cigarette Use Reduction83

Adverse events

Collected over From enrollment until end of follow-up, up to 28 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enhanced Care0/12 (0%)0/12 (0%)5/12 (41.7%)
Standard Care0/5 (0%)0/5 (0%)2/5 (40%)
Most frequent other events
Most frequent other events
EventEnhanced CareStandard Care
Sleep Disturbances/Abnormal DreamsGeneral disorders4/121/5
NauseaGeneral disorders1/121/5
Oral/DentalGeneral disorders1/121/5
Joint PainMusculoskeletal and connective tissue disorders0/121/5
HeadacheGeneral disorders1/120/5

Baseline characteristics

Numbers reported in Baseline Characteristics includes all enrolled participants who completed the informed consent, regardless of their attendance at subsequent study visits.

Age, Categorical
Age, Categorical(Participants)Enhanced CareStandard CareTotal
<=18 years000
Between 18 and 65 years11314
>=65 years639
Age, Continuous
Age, Continuous(Years)Enhanced CareStandard CareTotal
Mean61.8 ± 5.064.5 ± 6.262.5 ± 5.3
Sex: Female, Male
Sex: Female, Male(Participants)Enhanced CareStandard CareTotal
Female404
Male13619
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Enhanced CareStandard CareTotal
Hispanic or Latino101
Not Hispanic or Latino16622
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Enhanced CareStandard CareTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White15621
More than one race000
Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Enhanced CareStandard CareTotal
United States17623
09

Study locations

1 site
  • FDNY World Trade Center Health Program
    Brooklyn, New York 11201, United States
10

References and documents

Publications

  • Goldfarb DG, Moline T, Prezant DJ, Bars MP, Zeig-Owens R, Schwartz T, Cannon MF, Vaeth B, Arnsten JH, Webber MP, Nahvi S. Design of a randomized tobacco cessation trial among FDNY World Trade Center responders in a lung cancer screening program. Addict Sci Clin Pract. 2025 Aug 5;20(1):62. doi: 10.1186/s13722-025-00598-3. PubMed 40765018 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — The datasets generated and analyzed during the current study are not publicly available, but a deidentified dataset may be available from the principal investigator upon reasonable request.

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Oct 2025, 16 months.

Results were first posted in Nov 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2023
First posted
Aug 18, 2023
StartActual
May 31, 2024
Primary completionActual
Oct 13, 2025
CompletionActual
Oct 13, 2025
Results first posted
Nov 5, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 5, 2026
Primary outcomes
1 edited, 1 description edited
What changed in the outcomes
  • ChangedBefore Tobacco AbstinenceNow Number of Participants With (Biochemically Validated) Tobacco AbstinenceTime frame: From baseline (Week 0) through each research assessment visit up to the 12-week post EOT timepoint visit at 28 weeks → Weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint visit at 28 weeks
  • DescriptionEnrollment: how it is measured was reworded
Nov 5, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedPill Count Percentage - Varenicline (pill count) adherenceAdherenceTime frame: Up through the time of the final research visit at Week 16 → Baseline, Weeks 2, 4, 8, 12, and 16
  • ChangedBefore Counseling adherenceNow Number of Participants Who Attended Counseling Visit at Each Timepoint - Counseling AdherenceTime frame: From baseline (Week 0) through each visit up to the 12-week post EOT timepoint visit at 28 weeks → Baseline, Weeks 2, 4, 8, 12, 16, and the 12-week post EOT timepoint visit at 28 weeks
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Results posted
    Primary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • ChangedBefore Tobacco AbstinenceNow Number of Participants With (Biochemically Validated) Tobacco AbstinenceTime frame: From baseline (Week 0) through each research assessment visit up to the 12-week post EOT timepoint visit at 28 weeks → Weeks 2, 4, 8, 12, and 16 along with a 12-week post end of treatment (EOT) timepoint visit at 28 weeks
    • DescriptionEnrollment: how it is measured was reworded
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedPill Count Percentage - Varenicline (pill count) adherenceAdherenceTime frame: Up through the time of the final research visit at Week 16 → Baseline, Weeks 2, 4, 8, 12, and 16
    • ChangedBefore Counseling adherenceNow Number of Participants Who Attended Counseling Visit at Each Timepoint - Counseling AdherenceTime frame: From baseline (Week 0) through each visit up to the 12-week post EOT timepoint visit at 28 weeks → Baseline, Weeks 2, 4, 8, 12, 16, and the 12-week post EOT timepoint visit at 28 weeks
    + 4 other changes: identifiers, verification date, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT05997225
Collaborators
FDNY World Trade Center Health Program, National Institute for Occupational Safety and Health (NIOSH/CDC)
Responsible party
Sponsor
First posted
Aug 18, 2023
Start date
May 31, 2024
Primary completion
Oct 13, 2025
Completion
Oct 13, 2025
Results posted
Nov 5, 2026
Last update
Nov 5, 2026

Study contacts

Shadi Nahvi, MD, MS
principal investigator · Albert Einstein College of Medicine
David Goldfarb, PhD
principal investigator · FDNY

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion